Adverse mandibular bone effects associated with kidney disease are only partially corrected with bisphosphonate and/or calcium treatment

American Journal of Nephrology

Volumn 38, Issue 6, 2014, Pages 458-464

  Allen, Matthew R ^a   Chen, Neal X ^a   Gattone Ii, Vincent H ^a   Moe, Sharon M ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anti remodeling; C reactive protein; Oral bone; Parathyroid hormone; Zoledronate; Zoledronic acid

Indexed keywords

C REACTIVE PROTEIN; GLUCONATE CALCIUM; PARATHYROID HORMONE; ZOLEDRONIC ACID; CALCIUM; NITROGEN; PHOSPHORUS; TUMOR NECROSIS FACTOR ALPHA; UREA;

AGE DISTRIBUTION; ALVEOLAR BONE LOSS; ALVEOLAR CREST DISTANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MASS; CEMENTUM; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENAMEL; HYPOTHESIS; IMAGE ANALYSIS; MALE; MANDIBLE; MICRO-COMPUTED TOMOGRAPHY; MUSCULOSKELETAL SYSTEM PARAMETERS; NONHUMAN; PERIODONTITIS; PHENOTYPE; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; ANIMAL TISSUE; BONE REMODELING; CALCIUM BLOOD LEVEL; CEMENTUM ENAMEL JUNCTION TO ALVEOLAR CREST DISTANCE; DOSE RESPONSE; DRUG MEGADOSE; GLOMERULUS FILTRATION RATE; HYPERPARATHYROIDISM; INFLAMMATION; JAW DISEASE; LOW DRUG DOSE; MOUTH CAVITY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL;

ANIMALS; BONE DISEASES; C-REACTIVE PROTEIN; CALCIUM; DENTAL CEMENTUM; DENTAL ENAMEL; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; HETEROZYGOTE; IMIDAZOLES; INFLAMMATION; KIDNEY DISEASES; MALE; MANDIBLE; PARATHYROID HORMONE; PERIODONTITIS; PHENOTYPE; RATS; TOMOGRAPHY, X-RAY COMPUTED; X-RAY MICROTOMOGRAPHY;

EID: 84893056448     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000356335     Document Type: Article

References (35)

1. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al: Definition, evaluation, and classification of renal osteo-dystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDI-GO). Kidney Int 2006; 69:1945-1953. (Pubitemid 43924257)
2. Malluche HH, Monier-Faugere MC: Renal osteodystrophy: what's in a name? Presentation of a clinically useful new model to interpret bone histologic findings. Clin Nephrol 2006; 65:235-242.
3. Barreto FC, Barreto DV, Moyses RMA, Neves CL, Jorgetti V, Draibe SA, et al: Osteoporosis in hemodialysis patients revisited by bone his-tomorphometry: a new insight into an old problem. Kidney Int 2006; 69:1852-1857. (Pubitemid 43739215)
4. Kshirsagar AV, Moss KL, Elter JR, Beck JD, Offenbacher S, Falk RJ: Periodontal disease is associated with renal insufficiency in the Atherosclerosis Risk In Communities (ARIC) study. Am J Kidney Dis 2005; 45:650-657. (Pubitemid 40460753)
5. Proctor R, Kumar N, Stein A, Moles D, Porter S: Oral and dental aspects of chronic renal failure. J Dent Res 2005; 84:199-208. (Pubitemid 43822025)
6. Brockmann W, Badr M: Kidney Disease: Chronic Kidney Disease: pharmacological considerations for the dentist. J Am Dent As-soc 2010; 141:1330-1339.
7. Lee M, Chu E, El-Abbadi M, Foster B, Tomp-kins KA, Giachelli C, et al: Characterization of mandibular bone in a mouse model of chronic kidney disease. J Periodontol 2010; 81:300-309.
8. Craig RG: Interactions between chronic renal disease and periodontal disease. Oral Dis 2008; 14:1-7. (Pubitemid 350293996)
9. Eastell R, Walsh JS, Watts NB, Siris E: Bisphosphonates for postmenopausal osteoporosis. Bone 2011; 49:82-88.
10. Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, et al: Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 2007; 22:503-508. (Pubitemid 47457426)
11. Coco M: Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 2003; 14:2669-2676. (Pubitemid 37169355)
12. Jokihaara J, Pörsti IH, Kööbi P, Jolma PM, Mustonen JT, Saha HHT, et al: Treatment of experimental renal osteodystrophy with pamidronate. Kidney Int 2008; 74:319-327. (Pubitemid 352001244)
13. Lomashvili KA, Monier-Faugere MC, Wang X, Malluche HH, O'Neill WC: Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int 2009; 75:617-625.
14. Allen MR, Chen NX, Gattone VH, Chen X, Carr AJ, LeBlanc P, et al: Skeletal effects of zoledronic acid in an animal model of chronic kidney disease. Osteoporos Int 2012; 24: 1471-1481.
15. Allen MR, Ruggiero SL: A review of pharmaceutical agents and oral bone health: how os-teonecrosis of the jaw has affected the field; in Jensen OT (ed): Oral and Craniofacial Tissue Engineering. Hanover Park/IL, Quintessence Publishing, 2012, vol 5, pp 1-13.
16. Allen MR, Burr DB: The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 2009; 67:61-70.
17. Jeffcoat MK: Safety of oral bisphosphonates: controlled studies on alveolar bone. Int J Oral Maxillofac Implants 2006; 21:349-353. (Pubitemid 43962658)
18. Lane N, Armitage GC, Loomer P, Hsieh S, Majumdar S, Wang H-Y, et al: Bisphospho-nate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study. J Periodontol 2005; 76:1113-1122. (Pubitemid 41065401)
19. Cowley BD, Gudapaty S, Kraybill AL, Barash BD, Harding MA, Calvet JP, et al: Autosomal-dominant polycystic kidney disease in the rat. Kidney Int 1993; 43:522-534. (Pubitemid 23071934)
20. Cowley BD, Grantham JJ, Muessel MJ, Kraybill AL, Gattone VH: Modification of disease progression in rats with inherited polycystic kidney disease. Am J Kidney Dis 1996; 27: 865-879. (Pubitemid 26169040)
21. Moe SM, Chen NX, Seifert MF, Sinders RM, Duan D, Chen X, et al: A rat model of chronic kidney disease-mineral bone disorder. Kidney Int 2009; 75:176-184.
22. Aghaloo TL, Kang B, Sung EC, Shoff M, Ron-coni M, Gotcher JE, et al: Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat. J Bone Miner Res 2011; 26: 1871-1882.
23. Kubek D, Burr D, Allen M: Ovariectomy stimulates and bisphosphonates inhibit intra-cortical remodeling in the mouse mandible. Orthodont Craniofac Res 2010; 13:214-222.
24. Moe SM, Chen NX, Newman CL, Gattone VH II, Organ JM, Chen X, et al: A comparison of calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD. J Bone Miner Res 2013 (E-pub ahead of print).
25. Moe SM, Radcliffe JS, White KE, Gattone VH, Seifert MF, Chen X, et al: The pathophysiol-ogy of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat. J Bone Miner Res 2011; 26:2672-2681.
26. Weinberg MA, Bral M: Laboratory animal models in periodontology. J Clin Periodontol 1999; 26:335-340.
27. Oz H, Ebersole J: A novel murine model for chronic inflammatory alveolar bone loss. J Periodont Res 2010; 45:94-99.
28. Ferrario VF, Sforza C, Dellavia C, Galassi A, Rocca Rey L, Chiarelli G, et al: Facial changes in adult uremic patients on chronic dialysis: possible role of hyperparathyroidism. Int J Artif Organs 2005; 28:797-802. (Pubitemid 41535722)
29. Allen M, Burr D: Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know. Bone 2011; 49:56-65.
30. Gasser JA, Ingold P, Venturiere A, Shen V, Green JR: Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat. J Bone Miner Res 2007; 23:544-551.
31. Ruggiero SL, Dodson TB, Assael LA, Landes-berg R, Marx RE, Mehrotra B, et al: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-re-lated osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 2009; 67(suppl):2-12.
32. Bashutski JD, Eber RM, Kinney JS, Benavides E, Maitra S, Braun TM, et al: Teriparatide and osseous regeneration in the oral cavity. N Engl J Med 2010; 363:2396-2405.
33. Li X, Ominsky MS, Warmington KS, Niu QT, Asuncion FJ, Barrero M, et al: Increased bone formation and bone mass induced by scleros-tin antibody is not affected by pretreatment or co-treatment with alendronate in osteopenic, ovariectomized rats. Endocrinology 2011; 152:3312-3322.
34. Pepys MB, Hirschfield GM: C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-1812. (Pubitemid 38057722)
35. Chambrone L, Foz AM, Guglielmetti MR, Pannuti CM, Artese HPC, Feres M, et al: Peri-odontitis and chronic kidney disease: a systematic review of the association of diseases and the effect of periodontal treatment on estimated glomerular filtration rate. J Clin Peri-odontol 2013; 40:443-456.